Array Biopharma (ARRY) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.06 --0%
Revenue Growth %: -16.4%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: -16.4%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $44.52 million versus the consensus estimate of $30.99 million.
COLUMBUS / BRAF-mutant melanoma New Drug Application (NDA) expected to file in June or July
NEMO / NRAS-mutant melanoma target action date under the Prescription Drug User Fee Act (PDUFA) on June 30, 2017
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Kepler Cheuvreux Downgrades Volkswagen AG (VOW:GR) (VWAGY) to Hold
- Credo Tech (CRDO) PT Lowered to $245 at Mizuho
Create E-mail Alert Related Categories
Earnings, FDA, GuidanceRelated Entities
Earnings, PDUFASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
